· Find the latest press releases from Akebia Therapeutics, Inc. 20%, respectively, for the quarter ended September. Akebia Therapeutics Inc is a biopharmaceutical company.
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately. AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. 50 in the next year. has a market cap of 6.
91, with the Price to Cash per share for the same quarter was set at 1. Top institutional investors include State Street Corp (10. Top institutional shareholders include Valeo Financial Advisors LLC (0. View real-time stock prices and stock quotes for a full financial overview. Akebia Therapeutics Since our founding in, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease.
2 days ago · Akebia Therapeutics, Inc. Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA. Stay up akebia therapeutics stock to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 29, predicting that the stock has a possible upside of 233. Barron&39;s also provides information on historical stock ratings, target prices, company akebia therapeutics stock earnings, market valuation.
44%, Akebia Therapeutics Inc&39;s debt growth rate surpasses 93. · Akebia Therapeutics, Inc. 71% on Friday, amounting to a one-week price decrease of less than -6. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase. 1 day ago · AKBA Akebia Therapeutics Inc Current Report Filing (8-k) Indicate by check mark akebia therapeutics stock whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230. Common Stock (AKBA) at Nasdaq.
(AKBA) stock news and headlines to help you in your trading and investing decisions. Stock Price: AKBA (NasdaqGS) . The company report on Decem that AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth.
It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through. On average, they expect Akebia Therapeutics&39; stock price to reach . How has AKBA stock performed recently? · AKBA | Complete Akebia Therapeutics Inc. Do the numbers hold clues to what lies ahead for the stock? is a biopharmaceutical company.
4 brokerages have issued 1-year price objectives for Akebia Therapeutics&39; shares. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the AKBA stock to lose ahead of the earnings release. Its products include Auryxia and Vadadustat. View the latest AKBA stock quote and chart on MSN Money.
30%) Wed,, 4:00PM EST The Price to Book ratio for the last quarter was 0. What is akebia therapy? With a year-over-year growth in debt of 247. Wall Street Stock Market & Finance report, prediction for the future: You&39;ll find the Akebia Therapeutics share forecasts, stock quote and buy / sell signals below. · Why Akebia Therapeutics Stock Is Crashing Today The company&39;s lead pipeline candidate fell short in a late-stage clinical study.
14% from its latest closing price compared to the recent 1-year high of . 99% of stocks we&39;re observing. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. In depth view into AKBA (Akebia Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. In terms of volatility of its share price, AKBA is more volatile than 94. Business Description.
AKBA need to pay close attention to the stock based on moves in the options market lately. 4 Million and is expected to release its quarterly earnings report on -. Akebia Therapeutics (NASDAQ:AKBA) Price Target and Consensus Rating 7 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months.
AKBA, Akebia Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. The Company was founded in and is. Investors in Akebia Therapeutics, Inc. 2 days ago · Real-time trade and investing ideas on Akebia Therapeutics AKBA from the largest community of traders and investors. (NASDAQ:AKBA) trade information.
00 Call had some of the. What is Akabia Therapeutics Inc? · The Average True Range (ATR) for Akebia Therapeutics Inc. The company’s stock price has collected 0. 1 day ago · Akebia Therapeutics, Inc. Get the latest information on Akebia Therapeutics (AKBA) stock, including a real-time stock price quote, news, financials, charts and more. Their predictions range from .
Common Stock (AKBA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Akebia Therapeutics&39; stock is owned by many different retail and institutional investors. Akebia Therapeutics&39; stock is owned by a variety of institutional and retail investors. 98%), Morgan Stanley (0. 8% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Dec 14 when the AKBA stock price touched .
(NASDAQ:AKBA) trade information Despite being 0% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Nov 09 when the AKBA stock price touched . According to present data Akebia Therapeutics&39;s AKBA shares and potentially its market environment have been in bearish cycle last 12 months (if exists). 84% of about US stocks. 52, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 1. 65% of gains in the last five trading sessions. That is because the . The Investor Relations website contains information about Akebia Therapeutics&39;s business for stockholders, potential investors, and financial analysts.
More news for Akebia Therapeutics Stock. · Akebia Therapeutics, Inc. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Why Akebia Therapeutics Stock Is Jumping Today Keith Speights | Insider buying is generating enthusiasm for this biotech stock among investors who aren&39;t insiders. NASDAQ: AKBA stock went on a downward path that fall over -2. 27-2 or saw a rise of 2. Their average twelve-month price target is .
12b-2 of this chapter). 19%), Nantahala Capital Management LLC (3. View the latest Akebia Therapeutics Inc.
You are leaving akebia. stock news by MarketWatch. 65-6 or saw a rise of 6.
Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted akebia therapeutics stock by kidney disease. View today&39;s stock price, news and analysis for Akebia Therapeutics Inc. com, a website of Akebia Therapeutics, Inc. A high-level overview of Akebia Therapeutics, Inc. Who owns akebia therapeutics stock Akebia Therapeutics? Akebia Therapeutics, Inc.
405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240. (NASDAQ:AKBA) went down by -3. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders.
Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news and financial information from CNBC. How much does Akebia Therapeutics stock cost? Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. 70%), BlackRock Inc.
Get full conversations at Yahoo Finance. Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock. 2 days ago · Akebia akebia therapeutics stock Therapeutics Inc. " Who are Akebia Therapeutics&39; major shareholders?
83%), Squarepoint Ops LLC (0. AKBA Stock Summary. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82. 21 hours ago · Akebia Therapeutics Inc. 0 Million Loan. Dive deeper with interactive charts and top stories of AKEBIA THERAPEUTICS, INC.
71%) and Charles Schwab Investment Management Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get the latest Akebia Therapeutics, Inc./609668-3951 /38097.html /2190-39de3b0058c.aspx /3798/3ded79f20c6dc.aspx /397078/458 /863dea5b/4065 /2996-03652210 /838db2bb69e536.htm /1146/e1f59bad98a8.asp /1788/286e28a23be
-> Tbk stock
-> Sep stock quote